The FDA has banned the use of a synthetic red dye used in oral medicines, as well as foods and dietary supplements, more than ...

When healthcare brands leverage data to genuinely understand and connect with HCPs as unique individuals, the result is a ...

In Part 3 of our Life Sciences Industry Report 2025, we share content from the last twelve months that delved into the ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

Looking ahead to 2025, small biopharma will continue its deliberate and ROI-driven approach to technology adoption. At the ...

Generative artificial intelligence (GenAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

The 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry, focused ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...